Demeclocycline
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Demeclocycline: From Bacterial Infection Treatment to Chronic Ethmoidal Sinusitis
One-Sentence Summary
Demeclocycline is a tetracycline-class antibiotic with no currently active US market authorization on record. The TxGNN model predicts it may be effective for Chronic Ethmoidal Sinusitis, with 0 clinical trials and 1 publication (addressing disease pathology rather than demeclocycline treatment directly) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No regulatory record on file |
| Predicted New Indication | Chronic Ethmoidal Sinusitis |
| TxGNN Prediction Score | 99.14% |
| Evidence Level | L4 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for demeclocycline in this evidence pack. Based on known information, demeclocycline belongs to the tetracycline antibiotic class — a group whose antimicrobial and immunomodulatory properties have been established across a broad range of infectious and inflammatory conditions.
Chronic ethmoidal sinusitis is characterized by persistent bacterial colonization (commonly S. aureus, H. influenzae, and anaerobes), biofilm formation, and chronic inflammatory remodeling of the ethmoid mucosa and underlying bone. Tetracycline-class antibiotics carry three theoretical lines of action in this context: (1) direct antimicrobial activity against sinusitis-associated pathogens and biofilms; (2) matrix metalloproteinase (MMP) inhibition — particularly MMP-9 — which is implicated in the tissue and bone remodeling documented histologically in chronic sinusitis; and (3) anti-inflammatory effects including suppression of IL-1β, TNF-α, and eosinophil infiltration, pathways known to drive sinusoidal mucosal disease.
It is critical to note, however, that all mechanistic links are extrapolated from the broader tetracycline class — primarily from research on doxycycline and minocycline (including the clinical precedent of sub-antimicrobial doxycycline for periodontitis). Demeclocycline itself has no dedicated preclinical or clinical data in chronic ethmoidal sinusitis. The theoretical framework supports hypothesis generation only, not clinical translation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9546260 | 1998 | Histomorphometric Study | The Laryngoscope | Undecalcified histological analysis of ethmoid bone in chronic sinusitis; documents concurrent bone synthesis, resorption, and inflammatory cell infiltration — establishing the MMP-mediated tissue remodeling context that underpins the tetracycline mechanistic rationale |
US Market Information
No active US market authorizations on record for demeclocycline. The drug (historically marketed as Declomycin) is a tetracycline-class antibiotic that was previously available in the US but does not appear with active NDA entries in the current dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: There are no clinical trials and no direct literature evidence of demeclocycline being studied or used in chronic ethmoidal sinusitis. The single available publication documents disease pathology (ethmoid bone histomorphometry), not demeclocycline’s therapeutic effect. The drug is also not currently marketed in the US, raising significant feasibility concerns independent of the evidence gap.
To proceed, the following is needed:
- Mechanism of action data specific to demeclocycline (to distinguish its pharmacological profile from better-studied tetracyclines such as doxycycline or minocycline)
- In vitro studies assessing demeclocycline activity against sinusitis-relevant biofilm-forming organisms (e.g., S. aureus, H. influenzae)
- Preclinical animal model data evaluating MMP inhibition and anti-inflammatory effects in a sinusitis model
- Pharmacokinetic assessment of sinus tissue penetration following systemic administration
- Full safety review: package insert warnings, contraindications, and drug–drug interaction profile
- Regulatory and commercial feasibility assessment for demeclocycline availability
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.